QLGN Qualigen Therapeutics Inc

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K/A

(Amendment No. 1)

 

☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2022

 

or

 

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number 001-37428

 

Qualigen Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware		26-3474527
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

 

2042 Corte Del Nogal, Carlsbad, California 92011

(Address of principal executive offices) (Zip Code)

 

(760) 918-9165

Registrant’s telephone number, including area code

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class		Trading Symbol		Name of Exchange on Which Registered
Common Stock, par value $0.001 per share		QLGN		The Nasdaq Capital Market

 

Securities registered pursuant to Section 12(g) of the Act:

None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See definitions of “large accelerated filer, “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer	☐		Accelerated filer	☐
Non-accelerated filer	☒		Smaller reporting company	☒
			Emerging growth company	☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

As of June 30, 2022, the aggregate market value of the registrant’s common stock held by non-affiliates was approximately $21,943,148 based on the closing price for the common stock of $5.70 on that date. Shares of common stock held by the registrant’s executive officers and directors have been excluded from this calculation, as such persons may be deemed to be affiliates of the registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes.

 

As of April 11, 2023, there were 5,052,463 shares of the registrant’s common stock outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

None.

 

Audit Firm ID		Auditor Name		Auditor Location
23		BAKER TILLY US, LLP		San Diego, California

  

 

 

EXPLANATORY NOTE

 

Qualigen Therapeutics, Inc. (“Qualigen”) is filing this Amendment No. 1 on Form 10-K/A (this “Amendment”) to correct certain errors found in the Exhibit Index included in Part IV, Item 15 of its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission (the “SEC”) on May 2, 2023 (the “Original 10-K”), and to make certain changes to Exhibit 4.9, which is being refiled with this Amendment. Accordingly, the Exhibit Index has been amended and restated in its entirety to reflect these changes. Qualigen is also providing new certifications from its principal executive officer and principal financial officer as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended.

 

Except as described above, Qualigen has not modified or updated any disclosures contained in the Original 10-K. Accordingly, this Amendment does not reflect events occurring after the date of filing of the Original 10-K and therefore continues to speak only as of the date of the Original 10-K.

 

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules

 

(a) 3. Exhibits. See EXHIBIT INDEX

EXHIBIT INDEX

 

Exhibit No.		Description		Form		File No.		Exhibit		Filing Date
2.1		Contingent Value Rights Agreement, dated May 22, 2020, among the Company, John Beck in the capacity of CVR Holders’ Representative and Andrew J. Ritter in his capacity as a consultant to the Company.		8-K		001-37428		2.4		5/29/2020
3.1		Amended and Restated Certificate of Incorporation of Ritter Pharmaceuticals, Inc.		8-K		001-37428		3.1		7/1/2015
3.2		Certificate of Amendment to the Amended and Restated Certificate of Incorporation		8-K		001-37428		3.1		9/15/2017
3.3		Certificate of Amendment to the Amended and Restated Certificate of Incorporation		8-K		001-37428		3.1		3/22/2018
3.4		Certificate of Designation of Preferences, Rights and Limitations of Series Alpha Preferred Stock of the Company, filed with the Delaware Secretary of State on May 29, 2020		8-K		001-37428		3.1		5/29/2020
3.5		Certificate of Amendment to the Certificate of Incorporation of the Company, filed with the Delaware Secretary of State on May 22, 2020 [reverse stock split]		8-K		001-37428		3.2		5/29/2020
3.6		Certificate of Merger, filed with the Delaware Secretary of State on May 22, 2020		8-K		001-37428		3.3		5/29/2020
3.7		Certificate of Amendment to the Certificate of Incorporation of the Company, filed with the Delaware Secretary of State on May 22, 2020		8-K		001-37428		3.4		5/29/2020
3.8		Amended and Restated Bylaws of the Company, as of August 10, 2021		8-K		001-37428		3.1		8/13/2021
3.9		Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended.		8-K		001-37428		3.1		11/22/2022
4.1		Warrant, issued by the Company in favor of Alpha Capital Anstalt, dated May 22, 2020		8-K		001-37428		10.13		5/29/2020

 

 

4.2		Form of Warrant, issued by the Company in favor of GreenBlock Capital LLC and its designees, dated May 22, 2020 [post-Merger]		8-K		001-37428		10.10		5/29/2020
4.3		Common Stock Purchase Warrant in favor of Alpha Capital Anstalt, dated July 10, 2020		8-K		001-37428		10.2		7/10/2020
4.4		Common Stock Purchase Warrant in favor of Alpha Capital Anstalt, dated August 4, 2020		8-K		001-37428		10.3		8/4/2020
4.5		“Two-Year” Common Stock Purchase Warrant for 1,348,314 shares in favor of Alpha Capital Anstalt, dated December 18, 2020		8-K		001-37428		10.3		12/18/2020
4.6		“Deferred” Common Stock Purchase Warrant in favor of Alpha Capital Anstalt, dated December 18, 2020		8-K		001-37428		10.4		12/18/2020
4.7		Form of liability classified Warrant to Purchase Common Stock		10-K		001-37428		4.13		3/31/2021
4.8		Form of “service provider” compensatory equity classified Warrant		10-K		001-37428		4.14		3/31/2021
4.9*		Description of Common Stock
4.10		Amended and Restated Common Stock Purchase Warrant to GreenBlock Capital LLC, dated April 25, 2022		10-Q		001-37428		4.15		5/13/2022
4.11		Amended and Restated Common Stock Purchase Warrant to Christopher Nelson, dated April 25, 2022		10-Q		001-37428		4.16		5/13/2022
4.12		Common Stock Purchase Warrant for 2,500,000 shares in favor of Alpha Capital Anstalt, dated December 22, 2022		8-K		001-37428		4.1		12/22/2022

 

10.1+		Executive Employment Agreement, by and between Qualigen, Inc. and Michael Poirier, dated as of February 1, 2017 and as amended on January 9, 2018		8-K		001-37428		10.1		5/29/2020
10.2+		Executive Employment Agreement, by and between Qualigen, Inc. and Christopher Lotz, dated as of February 1, 2017 and as amended on January 9, 2018		8-K		001-37428		10.2		5/29/2020
10.3+		Executive Employment Agreement dated December 10, 2021 with Amy Broidrick		10-K		001-37428		10.53		3/31/2022
10.4+		2020 Stock Equity Incentive Plan		8-K		001-37428		10.20		5/29/2020
10.5+		Standard template of Stock Option Agreement for use under 2020 Stock Incentive Plan		8-K		001-37428		10.1		6/11/2020
10.6+		Form of Indemnification Agreement – Qualigen, Inc.		8-K		001-37428		10.21		5/29/2020
10.7		Exclusive Agreement (QN-247), by and between Qualigen, Inc. and University of Louisville Research Foundation, Inc. dated as of June 8, 2018		S-4/A		333-236235		10.58		3/13/2020
10.8		Amendment 1 to the Exclusive License Agreement (QN-247), by and between Qualigen, Inc. and University of Louisville Research Foundation, Inc., dated March 16, 2021		10-K		001-37428		10.8		5/2/2023

 

 

10.9		Amendment 2 to the Exclusive License Agreement (QN-247), by and between Qualigen, Inc. and University of Louisville Research Foundation, Inc., dated January 17, 2023		10-K		001-37428		10.9		5/2/2023
10.10		Exclusive License Agreement between the Company and University of Louisville Research Foundation (RAS), Inc., dated as of July 17, 2020		8-K		001-37428		10.4		8/4/2020
10.11		Amendment 1 to the Exclusive License Agreement (RAS), by and between Qualigen, Inc. and University of Louisville Research Foundation, Inc., dated March 16, 2021		10-K		001-37428		10.11		5/2/2023
10.12		License Agreement between Qualigen, Inc. and Advanced Cancer Therapeutics, LLC dated December 17, 2018		S-4/A		001-37428		10.59		3/13/2020
10.13		Novation Agreement among the Company, Qualigen, Inc. and Advanced Cancer Therapeutics, LLC dated July 29, 2020		10-K		001-37428		10.31		3/31/2021
10.14		Technology Transfer Agreement dated as of October 7, 2020 between Qualigen, Inc. and Yi Xin Zhen Duan Jishu (Suzhou) Ltd.		8-K		001-37428		10.1		10/9/2020
10.15		Novation Agreement among the Company, Qualigen, Inc. and University of Louisville Research Foundation, Inc. dated January 30, 2021		10-Q		001-37428		10.1		5/14/2021
10.16		Novation Agreement among the Company, Qualigen, Inc. and University of Louisville Research Foundation, Inc. dated March 1, 2021		10-Q		001-37428		10.2		5/14/2021

 

10.17+		Hire offer letter from the Company to Tariq Arshad, dated April 22, 2021		10-Q		001-37428		10.1		8/16/2021
10.18		Amendment to Technology Transfer Agreement between Yi Xin Zhen Duan Jishu (Suzhou) Ltd. and Qualigen, Inc., dated August 5, 2021		10-Q		001-37428		10.2		11/15/2021
10.19		Amendment to 2020 Stock Incentive Plan (approved by the Board of Directors on April 27, 2021 and by the Stockholders on August 9, 2021)		10-Q		001-37428		10.3		11/15/2021
10.20		Second Amendment to Lease with Bond Ranch LP dated December 15, 2021		10-K		001-37428		10.54		3/31/2022
10.21		First Deed of Variation to License Agreement with UCL Business Limited dated March 30, 2022		10-K		001-37428		10.21		5/2/2023
10.22		Series B Preferred Share Purchase Agreement between the Company and NanoSynex Ltd. dated April 29, 2022		10-Q		001-37428		10.1		5/13/2022
10.23		Share Purchase Agreement between the Company and Alpha Capital Anstalt dated April 29, 2022		10-Q		001-37428		10.2		5/13/2022
10.24		Master Agreement for the Operational and Technological Funding of NanoSynex between Qualigen Therapeutics, Inc. and NanoSynex Ltd., dated May 26, 2022		8-K		001-37428		10.1		6/2/2022
10.25+		Qualigen Therapeutics, Inc. 2022 Employee Stock Purchase Plan		10-Q		001-37428		10.1		11/14/2022

 

 

10.26+		Amendment No. 2 to the 2020 Stock Incentive Plan of Qualigen Therapeutics, Inc.		8-K		001-37428		10.1		11/22/2022
10.27+		Amendment No. 1 to the 2022 Employee Stock Purchase Plan of Qualigen Therapeutics, Inc.		8-K		001-37428		10.2		11/22/2022
10.28		Securities Purchase Agreement, dated December 21, 2022, by and between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt		8-K		001-37428		10.1		12/22/2022
10.29		8% Senior Convertible Debenture Due December 22, 2025		8-K		001-37428		10.2		12/22/2022
10.30		Registration Rights Agreement, dated December 22, 2022, by and between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt		8-K		001-37428		10.3		12/22/2022
10.31+		Letter to Michael P. Poirier, dated January 13, 2023, regarding compensatory changes		10-K		001-37428		10.31		5/2/2023
10.32+		Letter to Amy Broidrick, dated January 13, 2023, regarding compensatory changes		10-K		001-37428		10.32		5/2/2023
10.33+		Letter to Tariq Arshad, dated January 13, 2023, regarding compensatory changes		10-K		001-37428		10.33		5/2/2023
14.1		Code of Business Conduct and Ethics		8-K		001-37428		14.1		5/29/2020
21.1		Subsidiaries of the Registrant		10-K		001-37428		21.1		5/2/2023
23.1		Consent of Baker Tilly US, LLP, independent registered public accounting firm		10-K		001-37428		23.1		5/2/2023
24.1		Power of Attorney (included on signature page)		10-K		001-37428		24.1		5/2/2023
31.1*		Certificate of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*		Certificate of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certificate of principal executive officer and principal financial officer pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.		10-K		001-37428		32.1		5/2/2023
101.INS#		Inline XBRL Instance Document.
101.SCH#		Inline XBRL Taxonomy Extension Schema Document.
101.CAL#		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF#		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB#		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE#		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed or furnished herewith.

** Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedules will be furnished to the SEC upon request.

+ Indicates management contract or compensatory plan or arrangement.

# XBRL (Extensible Business Reporting Language) information is furnished and not filed herewith, is not a part of a registration statement or Prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Qualigen Therapeutics, Inc.
	By:	/s/ Michael S. Poirier
		Michael S. Poirier
		Chairman of the Board, Chief Executive Officer
Date: July 7, 2023

 

 

 

Exhibit 4.9

 

QUALIGEN THERAPEUTICS, INC.

DESCRIPTION OF COMMON STOCK

 

Qualigen Therapeutics, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) – common stock, par value $0.001 per share (the “Common Stock”). The Common Stock trades on The Nasdaq Capital Market under the trading symbol “QLGN.”

 

The following summary description sets forth some of the general terms and provisions of the Common Stock. Because this is a summary description, it does not contain all of the information that may be important to you. For a more detailed description of the Common Stock, you should refer to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate”) and the Amended and Restated Bylaws (the “Bylaws”), which are filed as exhibits to the Annual Report on Form 10-K to which this description is filed as an exhibit.

 

The Company’s authorized capital stock consists of 240,000,000 shares, all with a par value of $0.001 per share, 225,000,000 of which are designated as Common Stock and 15,000,000 of which are designated as preferred stock, consisting of (i) 9,500 shares that have been designated Series A Convertible Preferred Stock, (ii) 6,000 shares that have been designated as Series B Convertible Preferred Stock, (iii) 1,880 shares that have been designated as Series C Convertible Preferred Stock, and (iv) 7,000 shares that have been designated Series Alpha Preferred Stock.

 

Common Stock

 

Pursuant to the terms of our Certificate, the holders of Common Stock are entitled to one vote per share of Common Stock held of record by such holder on all matters on which stockholders generally are entitled to vote; provided, however, that, except as otherwise required by law, holders of Common Stock, as such, are not entitled to vote on any amendment to the Certificate (including any Certificate of Designation relating to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled either separately or together with the holders of one or more other such series, to vote on such amendment pursuant to the Certificate (including any Certificate of Designation relating to any series of Preferred Stock) or pursuant to the Delaware General Corporation Law (the “DGCL”).

 

Subject to the prior rights of holders of all classes of stock at the time outstanding having prior rights as to dividends, the holders of Common Stock will be entitled to receive, when and as declared by the board of directors, out of any assets of the Company legally available for such purpose, such dividends, distributed ratably among the holders of the Common Stock in proportion to the number of shares of such Common Stock owned by each such holder, as may be declared from time to time by the board of directors.

 

In the event of our liquidation, dissolution or winding up, either voluntarily or involuntarily, subject to the prior rights of holders of all classes of stock at the time outstanding having prior rights as to distributions in the event of liquidation, dissolution or winding up of the Company, and after any and all distributions are made in accordance therewith, the remaining assets and funds of the Company legally available for distribution will be distributed ratably among the holders of the Common Stock in proportion to the number of shares of such Common Stock owned by each such holder.

 

The holders of Common Stock will have no preemptive or conversion rights or other subscription rights. There will be no redemption or sinking fund provisions applicable to our common stock.

 

 

Anti-Takeover Effects of Delaware Law and Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws

 

The provisions of Delaware law and the Company’s Certificate and Bylaws, could discourage or make it more difficult to accomplish a proxy contest or other change in our management or the acquisition of control by a holder of a substantial amount of the Company’s voting stock. It is possible that these provisions could make it more difficult to accomplish, or could deter, transactions that stockholders may otherwise consider to be in their best interests or in the Company’s best interests. These provisions are intended to enhance the likelihood of continuity and stability in the composition of the Company’s board of directors and in the policies formulated by the board of directors and to discourage certain types of transactions that may involve an actual or threatened change of control of the Company. These provisions are designed to reduce the Company’s vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy fights. Such provisions also may have the effect of preventing changes in the Company’s management.

 

Delaware Statutory Business Combinations Provision. The Company is subject to the anti-takeover provisions of Section 203 of the DGCL. Section 203 prohibits a publicly-held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. For purposes of Section 203, a “business combination” is defined broadly to include a merger, asset sale or other transaction resulting in a financial benefit to the interested stockholder, and, subject to certain exceptions, an “interested stockholder” is a person who, together with his or her affiliates and associates, owns, or within three years prior, did own, 15% or more of the corporation’s voting stock.

 

Election and Removal of Directors. Except as may otherwise be provided by the DGCL, any director or the entire board of directors may be removed, with or without cause, at an annual meeting or a special meeting called for that purpose, by the affirmative vote of the majority of shares then entitled to vote at an election of directors. Vacancies on the Company’s board of directors resulting from the death, resignation, removal or otherwise of directors and newly created directorships resulting from any increase in the number of directors may be filled solely by the affirmative vote of a majority of the remaining directors then in office (although less than a quorum) or by the sole remaining director. This system of electing and removing directors may discourage a third party from making a tender offer or otherwise attempting to obtain control of the Company, because it generally makes it more difficult for stockholders to replace a majority of the Company’s directors. The Company’s Certificate and Bylaws do not provide for cumulative voting in the election of directors.

 

Advance Notice Provisions for Stockholder Proposals and Stockholder Nominations of Directors. The Company’s Bylaws provide that, for nominations to the board of directors or for other business to be properly brought by a stockholder before a meeting of stockholders, the stockholder must first have given timely notice of the proposal in writing to the Company’s Secretary. For an annual meeting, a stockholder’s notice generally must be delivered not less than 90 days or more than 120 days prior to the anniversary of the previous year’s annual meeting.

 

Special Meetings of Stockholders. Special meetings of the stockholders may be called at any time only by the Chairman of the board of directors, the Chief Executive Officer or the President, subject to the rights of the holders of any series of preferred stock then outstanding.

 

Blank-Check Preferred Stock. The Company’s board of directors is authorized to issue, without stockholder approval, preferred stock, the rights of which will be determined at the discretion of the board of directors and that, if issued, could operate as a “poison pill” to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that the board of directors does not approve.

 

Transfer Agent and Registrar

 

The transfer agent and registrar for our common stock is Equiniti Trust Company.

 

 

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Michael S. Poirier, certify that:

 

1.	I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K of Qualigen Therapeutics, Inc., a Delaware corporation, for the year ended December 31, 2022;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

July 7, 2023	By:	/s/ Michael S. Poirier
	Name:	Michael S. Poirier
	Title:	Chief Executive Officer

 

 

 

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Christopher L. Lotz, certify that:

 

1.	I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K of Qualigen Therapeutics, Inc., a Delaware corporation, for the year ended December 31, 2022;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

July 7, 2023	By:	/s/ Christopher L. Lotz
	Name:	Christopher L. Lotz
	Title:	Chief Financial Officer (Principal Financial Officer)

 

 

v3.23.2

Cover - USD ($)	12 Months Ended
	Dec. 31, 2022	Apr. 11, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K/A
Amendment Flag	true
Amendment Description	Qualigen Therapeutics, Inc. (“Qualigen”) is filing this Amendment No. 1 on Form 10-K/A (this “Amendment”) to correct certain errors found in the Exhibit Index included in Part IV, Item 15 of its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission (the “SEC”) on May 2, 2023 (the “Original 10-K”), and to make certain changes to Exhibit 4.9, which is being refiled with this Amendment. Accordingly, the Exhibit Index has been amended and restated in its entirety to reflect these changes. Qualigen is also providing new certifications from its principal executive officer and principal financial officer as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended.
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-37428
Entity Registrant Name	Qualigen Therapeutics, Inc.
Entity Central Index Key	0001460702
Entity Tax Identification Number	26-3474527
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2042 Corte Del Nogal
Entity Address, City or Town	Carlsbad
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92011
City Area Code	(760)
Local Phone Number	918-9165
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	QLGN
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 21,943,148
Entity Common Stock, Shares Outstanding		5,052,463
Documents Incorporated by Reference [Text Block]	None.
ICFR Auditor Attestation Flag	false
Auditor Firm ID	23
Auditor Name	BAKER TILLY US, LLP
Auditor Location	San Diego, California

---